Location History:
- Hoväs, SE (2006 - 2010)
- Hovas, SE (2013 - 2016)
Company Filing History:
Years Active: 2006-2016
Title: Ann Hellström: Innovator in Prematurity Treatment
Introduction
Ann Hellström is a prominent inventor based in Hoväs, Sweden. She has made significant contributions to the field of medicine, particularly in the treatment of complications arising from prematurity. With a total of 4 patents to her name, her work has the potential to improve the lives of many premature infants.
Latest Patents
Among her latest patents is a groundbreaking invention titled "Methods for treatment of complications of prematurity comprising administration of IGF-I and IGFBP-3." This invention focuses on a composition that includes Insulin Growth Factor I (IGF-I) or an analog, combined with Insulin Growth Factor Binding Protein (IGFBP) or an analog. The molar ratio of IGF-I to IGFBP is designed to be lower than equimolar, specifically in the range from 1:20 to 1:3.33. This composition is intended for treating patients suffering from complications related to preterm birth, very preterm birth, and extremely preterm birth.
Another notable patent is "Method and product for treatment and/or prevention of complications of prematurity." Similar to her previous work, this invention also involves a composition of IGF-I and IGFBP, aimed at addressing the same medical challenges associated with premature births.
Career Highlights
Throughout her career, Ann Hellström has worked with esteemed organizations such as Premacure AB and Children's Medical Center Corporation. Her experience in these companies has allowed her to develop innovative solutions that address critical health issues faced by premature infants.
Collaborations
Ann has collaborated with notable professionals in her field, including Lois Elaine Smith and Chatarina Lofqvist. These partnerships have further enriched her research and development efforts.
Conclusion
Ann Hellström's contributions to the treatment of complications from prematurity highlight her dedication to improving neonatal care. Her innovative patents and collaborations reflect her commitment to advancing medical science for the benefit of vulnerable patients.